chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Admitted with right lower lobe pneumoina, bilateral leg weakness, COPD, CAD, hypertension, hyperlipidemia.  No deterioration of respiratory systems, spontaneous recovery started but IgD started for quick recovery. The weakness is almost gone on discharge 01/06/2011.
Patient was administered PDX to right thigh at about 04:00PM.  Parent returned at 04:05PM with complaint of redness and swelling to injections site.  Patient was applied cold compress and was done a CBC.  The doctor advised and patient is for return tomorrow 07/07/05 for a follow up.
Left upper thigh covering injection site, 4 in x 5 in circular, blanchable, warm to touch, red lesion, very dense. Minimal swelling, noted after immunization. Worsening since last night. Cephalexin prescribed.
Palpitations 1 day pain in arm 14 days hives on back of arm 2 days
Near syncope (multiple events); vomiting (multiple events); chills; headache Onset approx. 12 hours following vaccine.  Rapid onset with little to no warning, lasting approx. 2-3 hours.
6:30 am Dec 22nd went I to AFib and passed out fracturing my skull. Admitted overnight in hospital and had to have heart shocked back to normal sinus rythm.
very sleepy; I feel nervous; I feel like something is not ok; tachycardia; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (very sleepy), ANXIETY (I feel nervous), MALAISE (I feel like something is not ok) and TACHYCARDIA (tachycardia) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 24-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Sep-2021, the patient experienced SOMNOLENCE (very sleepy), ANXIETY (I feel nervous), MALAISE (I feel like something is not ok) and TACHYCARDIA (tachycardia). At the time of the report, SOMNOLENCE (very sleepy), ANXIETY (I feel nervous) and MALAISE (I feel like something is not ok) outcome was unknown and TACHYCARDIA (tachycardia) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Sep-2021, Blood pressure measurement: 128/75 (High) 128/75.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  Patient did not have history of myocarditis/pericarditis. However, patient mentioned that his heart was big. Patient's blood pressure was also high 128/75 (Patient usually had it around 65/70).
This spontaneous report was received from a nurse concerning a patient of unknown age and gender. Pertinent medical history, concurrent conditions, drug allergies/reactions and concomitant medications were not reported. On 22-MAY-2018, the patient was vaccinated with an improperly stored dose of PNEUMOVAX23 injection, lot # R002354, expiry date: 17-DEC-2018, intramuscularly for prophylaxis (strength, dose and dosage schedule were not provided). No adverse effects were reported. The temperature excursion and time frame for PNEUMOVAX23 were 10.9°C during 1 hour and 15 minutes. No previous temperature excursion was reported. Data logger was reported.
Welts around waistband of pants and on backs of both arms. They were itchy, raised, but not red. Applied spray his wife had used for shingles (helps itching). Lasted a couple of hours. Went away and came back the next day on legs and back. Resolved and returned again this morning.
rt arm pain, tendonitis/bursitis 1wk following vax;no prior hx of tendonitis or should problems;
Initial report was received from a patient on 07 October 2011. A 70-year-old female patient had received ADAEL and FLUZONE HIGH-DOSE (lot numbers, route and site of administration not reported) on 02 October 2011. On an unspecified date, the patient arm was painful when "lifting weights" or moves her arm over her head. No further information was available at the time of the report. The patient outcome was not reported. Documents held by sender: None.
Patient complained of nausea, coughing after receiving Pfizer vaccine dose 2. Observed by provider on site and discharged to home.
Pain at the injection site; Swelling at the injection site; Headache; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Pain at the injection site), VACCINATION SITE SWELLING (Swelling at the injection site) and HEADACHE (Headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced VACCINATION SITE PAIN (Pain at the injection site), VACCINATION SITE SWELLING (Swelling at the injection site) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (Pain at the injection site), VACCINATION SITE SWELLING (Swelling at the injection site) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided
Patient tested positive for COVID-19, he is asymptomatic. There are 10 members in his household, 9 of them have tested positive and 3 are fully vaccinated.
Hospitalized 1/3/22 - 1/8/22 and 1/14/22 - 1/26/22. During first admission, received remdesivir and discharged on O2. On second admission, presented with increased generalized weakness, fever, hypoxemia. Required continuous BiPAP on max settings. Chest tube placed and intubation discussed but family opted to transition to comfort care. Pt expired shortly after BiPAP was removed.
Pt was injected with TDAP vaccine in the (R) shoulder. Pt c/o tenderness to injection site and rash on chest. Denies any n/v/d/f/c.h. Pt is to report to acute care for further treatment.
Contracted COVID-19/COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Contracted COVID-19/COVID-19) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product PANCREATIN (CREON) for an unknown indication.    No Medical History information was reported.   On 17-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started PANCREATIN (CREON) (Oral) at an unspecified dose. In 2021, the patient experienced COVID-19 (Contracted COVID-19/COVID-19). In 2021, COVID-19 (Contracted COVID-19/COVID-19) had resolved. Not Provided          No concomitant medications were reported. It was unknown if patient was enrolled in a COVID-19 vaccine trial. No treatment medications were reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment: This spontaneous case concerns a 54-years-old female patient, with no medical history reported, who experienced the unexpected non serious AESI of COVID-19, that occurred in context to a dose with mRNA-1273 vaccine. Patient had started with non-company product PANCREATIN (CREON) for an unknown indication. No further information on risk factors, co morbidities and treatment was available in the report. The event outcome was resolved. Ongoing COVID-19 pandemic could be confounding for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events seriousness was assessed as per medical judgement and available information.; Sender's Comments: This spontaneous case concerns a 54-years-old female patient, with no medical history reported, who experienced the unexpected non serious AESI of COVID-19, that occurred in context to a dose with mRNA-1273 vaccine. Patient had started with non-company product PANCREATIN (CREON) for an unknown indication. No further information on risk factors, co morbidities and treatment was available in the report. The event outcome was resolved. Ongoing COVID-19 pandemic could be confounding for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events seriousness was assessed as per medical judgement and available information.
Metallic taste in the mouth; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (Metallic taste in the mouth) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, the patient experienced DYSGEUSIA (Metallic taste in the mouth). At the time of the report, DYSGEUSIA (Metallic taste in the mouth) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication list was not provided. Treatment information was not provided.
Swelling and pain to right deltoid (injection site). Swelling to right Axillary described as "size of baseball". Swelling and pain radiated to right side of neck. Pain radiated to mid sternum, right side of chest, down right arm. Intermittent numbness and tingling to right arm, may include entire arm or sections of right arm. Moving from sit to stand, pain in right side groin area. Pain overall rated at 5/10. Right axillary pain 7/10. 01/22/2021, pain has "significantly improved",  numbness resolved on 01/20/2020, tingling continues at this time. Overall rated pain currently 3/10, continues in all sites listed above. Visited PCP on 01/20/2021, prescribed 800mg 3 times daily for pain. Recommended to follow up Public Health or CDC. PCP had no further guidance for future vaccinations, client would need to make that decision independently. PCP recommended follow up if symptoms continue or worsen.
05/16/07 PHONE CALL TO CLINIC FROM ARNP.  CLIENT HAS RAISED RED AREA APROX. 10cm x 8cm AREA ON LEFT ARM.  NO OTHER PROBLEMS PER PROVIDER.
Patient first experienced a rash consisting of raised bumps on the skin of both arms.   About 15-20 minutes later, patient vomited several times, though this resolved after another 15-20 minutes.
This spontaneous report was received from a physician and a practice manager and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapy were not reported. On 08-JUN-2016, the patient was vaccinated with improperly stored dose of PNEUMOVAX 23 0.5 ml prefilled syringe (lot # L024132, expiration date: 21-JAN-2017; dose and route were not provided). The vaccine was exposed to following separate temperature excursions: first lasting for 168 hours, with the lowest recorded temperature of 32 degrees Fahrenheit and the second lasting for 712 hours, with the lowest recorded temperature of 34 degrees Fahrenheit. The vaccine was stored in a refrigerator. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
i received .5cc t dap on 10/09/07-very high up on left arm. pain began that evening. became progressively worse-unable to move arm without severe pain. called the clinic10/15/07, advised to continue working out the arm-stated pain may continue more than 2days-may be hyper reaction. expressed my concern that injection may have been placed too high(trainee placed injection-name?) pain continued to worsen. called clinic again 10/19/07-connected to message machine, which was not taking messages. pain prgressed to excruciating over the weekend. called clinic again 10/22/07-left message with appt.
Information has been received from a registered nurse referring to female patient of unknown age.  The patient's medical history, concurrent condition and concomitant medication were unknown. On unspecified date, the patient was vaccinated with a dose of improperly stored GARDASIL 9 (dose and route unknown, lot # M035486, expiration date: 05-JUN-2019) for prophylaxis. The vaccine was stored in -1.5 degrees Celsius for 2 hours 53 minutes. There was no previous temperature excursion. The call was because of a data logger. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
I am unsure if this is from the vaccine or not but the lady that called me from V-Safe asked me to fill out this form. Pancreatitis , treated with fluids and various medications, hospitalized for six days. Discharged home to follow up with primary doctor later this week.
Nine days after receiving MMR vaccine, the pt's temperature went up. When he was seen in the evening, a "generalized febrile seizure" was noted.
Sleeplessness and Insomnia all night untill through 6:00am the next day when I had to go take sleep inducing medicines from a gas station
Oral yeast infection tx w/ mycostatin QID lasted approx 2-2 1/2 wks.
Pt was admitted on 4/3 for MS flair and recurrent UTI. Pt tested for COVID on 4/5 due to nursing home placement and tested positive, but asymptomatic.
Started afternoon of Apr 16. 100.2 F fever, chills, aches in joints, tiredness, really sore left arm at injection site.  Most symptoms gone by afternoon Apr 17.
AFTER GETTING VACCINE THE PATIENT STARTED FEELING DIZZY , HE GOT VERY SWEATY , FELT LIKE FAINTING
1-8-08 had wart removed from (R) buttock. MD had tested, biopsy result HPV. Does not know what strand. 7-08 had to have 2nd wart removed. Client and mother concerned the HPV may have been caused by immunization.
This case was reported by a consumer and described the occurrence of narcolepsy in a adult female patient who received Hepatitis B vaccine. Co-suspect products included H1N1 vaccine. On an unknown date, the patient received Hepatitis B vaccine at an unknown dose and H1N1 vaccine at an unknown dose. On an unknown date, an unknown time after receiving Hepatitis B vaccine and H1N1 vaccine, the patient experienced narcolepsy (serious criteria GSK medically significant), sleep apnea, daytime sleepiness, muscle weakness, fatigue and nightmare. On an unknown date, the outcome of the narcolepsy, sleep apnea, daytime sleepiness, muscle weakness, fatigue and nightmare were not recovered/not resolved. It was unknown if the reporter considered the narcolepsy, sleep apnea, daytime sleepiness, muscle weakness, fatigue and nightmare to be related to Hepatitis B vaccine. Additional details were provided as follows: The patient had worked in the healthcare industry from 2007-2010. The patient received Hepatitis B and influenza with H1N1 vaccines. Since 2009, the patient always had sleep apnea and have worn a continuous positive airway pressure (CPAP), due to this she had struggled over time with daytime sleepiness. Things changed and the daytime sleepiness progressively worsened. The patient's regular physician sent her to an ENT and she had surgery to help her apnea. Her severe apnea improved between the surgery and the CPAP, but the daytime sleepiness turned scary, she fell asleep while driving daily, muscle weakness and fatigue took over her body and nothing was helping. The ENT sent the patient to a specialist with a sleep disorder degree. He suspected narcolepsy. The patient had to take a stimulant to keep her awake to function, since she was a mother and had a career too. With the help of a stimulant, she can stay awake long enough to get her through the day, but every 2 hours she was hit with this overwhelming exhaustion. Sometimes it was so bad that she went into automatic behavior, felt like sleeping with eyes open. The patient's sleep study showed that she entered REM (Rapid eye movement) within 5 minutes of sleep and did not come out of it. She struggled daily to get out of bed and with each day it as a guess on how she would feel. The patient's blood test showed low levels of hypocretin. Her thin frame was now considered obese. The patient experienced terrifying nightmare, where she screamed out and jump in her sleep and was classic narcolepsy. The patient knew and remembered the narcolepsy cases in another country in 2009. She inquired about how many cases had been reported after H1N1 in this country. She had taken shots since 2003, with her current symptoms and asked should she not receive the vaccines and if she did would it worsen her current symptoms. She inquired about her low levels of hypocretin could be genetic and should she not allow her children to be vaccinated with the H1N1 to be safe. Currently they had also received H1N1 vaccines since 2003 and she was worried about seeing the same symptoms in them.
child recv vax & child mom broke out in apparent varicella;no adverse rxn in the child;
No adverse effects; improperly stored vaccine; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's current condition, concomitant medications, pertinent medical history, drug reactions/allergies were not reported. On 21-SEP-2019, the patient was administered with one dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) lot number R030924, expiry date 10-JUL-2020 (dose, strength, frequency were unknown) via oral route (defaulted) for prophylaxis which was improperly stored (product storage error). The vaccine underwent a temperature excursion of 0.24 Celsius for time frame of 5 hours 30 minutes. Data logger was involved. There was no previous temperature excursion. There were no adverse effects reported. There was no product quality complaint involved.
Hot Flashes from getting the shot from the Pfizer shot; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number: ER2613, Expiry date: not reported), via an unspecified route of administration on an unspecified date as dose number unknown, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient had hot flashes from getting the shot from the pfizer shot. The consumer reported that have they heard of any side effect of older people of having hot flashes from getting the shot from the Pfizer shot. The outcome of the event was unknown.   No follow-up attempts possible. No further information expected.
patient got a shot a 11:35am in the left arm at 11:47 the patient reported that he was having hives on his arms and chest. After looking at him we gave him oral benadryl at 11:50 at which time we had him sit for another 10 minutes to which he said he was not having any breathing problems or shortness of breath. He was here with his wife who he left with, he said he felt that he was fine to go home, we advised him to call the health department before his second shot
Red, swollen (round as a tennis ball and raised 1/2 inch), and itching at injection site.  Size of red itchy area expanded in size over 3 days.  Also experienced swollen and painful lymph nodes under left arm, left collar bone at base of neck and up to behind left ear.  Went to urgent care on day 3 and was treated for possible cellulitis with Cephalexin for 10 days.
3-14-07 When putting on pajamas on Wed night mother noticed left upper leg swollen, red and warm to touch. Child taken to ER. Received steroid IM and Benadryl. Prescription given for antibiotic. 3-15-07 Child taken to pediatric doctor. Assessment made of left upper leg confirmed that left leg was reaction to DTaP.
pain at the injection site; muscle aches; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2), administration date 24Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "recovered", described as "pain at the injection site"; MYALGIA (non-serious), outcome "unknown", described as "muscle aches". Additional information: It was asked if patient could take TYLENOL to relieve the pain.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
about 8 hrs p/vax pt started w/urticaria & swelling of face; wheezing started 1/2 hrs of urticaria;
Strength less than half in his right hand; Paralyses started 72 hours after vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PARALYSIS (Paralyses started 72 hours after vaccine) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 15-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-May-2021, the patient experienced ASTHENIA (Strength less than half in his right hand). In May 2021, the patient experienced PARALYSIS (Paralyses started 72 hours after vaccine) (seriousness criterion medically significant). At the time of the report, PARALYSIS (Paralyses started 72 hours after vaccine) and ASTHENIA (Strength less than half in his right hand) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication reported. Patient received covid vaccine on 15 May 2021. Per father son paralyses started 72 hours after strength less than half in his right hand. No treatment information was provided  Company Comment : Very limited information regarding the events has been provided at this time.  Further information has been requested.; Sender's Comments: Very limited information regarding the events has been provided at this time.  Further information has been requested.
This spontaneous report as received from a pharmacist refers to a 30 year old male patient. The patient medical history included allergy to BACTRIM, allergy to KEFLEX and allergy to penicillin (manufacturers unspecified) and post stem cell transplantation. On 16-MAY-2014, the patient was vaccinated with M-M-R II (injection, subcutaneously, dose and frequency: not reported) (lot #, exp date: unknown). On approximately 06-JUN-2014 (reported as about 3 weeks after receiving M-M-R II, the patient developed pneumonitis and a measles like rash. The reporter stated that the patient had significant disability which was inflammation to the lung tissue. On an unknown date in 2014, computerized tomogram (CT) to diagnose pneumonitis was performed. The patient sought medical attention. He contacted physician (date unknown). On 01-JUL-2014, the patient was admitted to hospital. The outcome of inflammation to the lung tissue/pneumonitis and a measles like rash was unknown. Relatedness between inflammation to the lung tissue/pneumonitis and a measles like rash and M-M-R II was not reported. Inflammation to the lung tissue/pneumonitis and measles like rash were considered to be life-threatening and disabling by the reporter. Additional information has been requested.